<div id="readability-page-1"><p>4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Get Free Report) insider Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $10.90, for a total value of $17,821.50. Following the sale, the insider directly owned 3,594 shares of the company's stock, valued at $39,174.60. This trade represents a 31.27% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities &amp; Exchange Commission, which is available through the SEC website.</p><p>Scott Bizily also recently made the following trade(s): </p><ul><li>On Monday, November 17th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.59, for a total value of $17,314.65. </li><li>On Friday, October 24th, Scott Bizily sold 2,678 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $12.00, for a total value of $32,136.00. </li><li>On Thursday, October 16th, Scott Bizily sold 1,635 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $10.17, for a total value of $16,627.95. </li><li>On Thursday, October 9th, Scott Bizily sold 2,408 shares of 4D Molecular Therapeutics stock. The shares were sold at an average price of $10.00, for a total transaction of $24,080.00. </li><li>On Tuesday, September 23rd, Scott Bizily sold 2,407 shares of 4D Molecular Therapeutics stock. The stock was sold at an average price of $8.00, for a total transaction of $19,256.00. </li></ul><h2>4D Molecular Therapeutics Price Performance</h2><p>Shares of NASDAQ:FDMT traded down $0.01 during trading on Friday, hitting $8.68. 4,815,801 shares of the company were exchanged, compared to its average volume of 883,375. The firm's 50 day moving average price is $10.68 and its 200-day moving average price is $7.47. 4D Molecular Therapeutics, Inc. has a 12-month low of $2.23 and a 12-month high of $12.34. The stock has a market capitalization of $495.93 million, a P/E ratio of -2.31 and a beta of 2.96. </p><p>4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last posted its earnings results on Monday, November 10th. The company reported ($1.01) EPS for the quarter, beating analysts' consensus estimates of ($1.02) by $0.01. 4D Molecular Therapeutics had a negative net margin of 174,314.17% and a negative return on equity of 47.27%. The firm had revenue of $0.09 million for the quarter, compared to the consensus estimate of $0.40 million.  As a group, equities research analysts anticipate that  4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current year. </p><h2>Hedge Funds Weigh In On 4D Molecular Therapeutics</h2><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in FDMT. Acadian Asset Management LLC lifted its holdings in  4D Molecular Therapeutics by 1,103.4% in the first quarter. Acadian Asset Management LLC now owns 400,606 shares of the company's stock valued at $1,290,000 after acquiring an additional 367,317 shares during the period.  Invesco Ltd. grew its stake in shares of  4D Molecular Therapeutics by 318.3% during the 1st quarter. Invesco Ltd. now owns 117,768 shares of the company's stock worth $380,000 after purchasing an additional 89,611 shares during the period.  Russell Investments Group Ltd. purchased a new position in shares of  4D Molecular Therapeutics in the 1st quarter valued at about $63,000.  Nuveen LLC acquired a new stake in shares of  4D Molecular Therapeutics in the first quarter valued at about $486,000.  Finally, Kera Capital Partners Inc. purchased a new stake in  4D Molecular Therapeutics during the second quarter worth about $89,000. Institutional investors and hedge funds own  99.27% of the company's stock. </p><h2>Analyst Upgrades and Downgrades</h2><p>Several analysts have recently weighed in on FDMT shares. Chardan Capital  reissued a &#34;buy&#34; rating and issued a $26.00 target price on shares of 4D Molecular Therapeutics in a report on Thursday. Royal Bank Of Canada boosted their price objective on 4D Molecular Therapeutics from $26.00 to $32.00 and gave the company an &#34;outperform&#34; rating in a research note on Tuesday, November 11th. Barclays lowered their target price on shares of 4D Molecular Therapeutics from $38.00 to $33.00 and set an &#34;overweight&#34; rating on the stock in a research report on Tuesday, November 11th. Morgan Stanley upgraded shares of 4D Molecular Therapeutics from an &#34;underweight&#34; rating to an &#34;equal weight&#34; rating in a research report on Friday, November 7th. Finally, Weiss Ratings  reiterated a &#34;sell (d-)&#34; rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, October 8th. Eight research analysts have rated the stock with a Buy rating, two have issued  a Hold rating and one  has given a Sell rating to the company. Based on data from MarketBeat, 4D Molecular Therapeutics currently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $28.70.</p><p><b>View Our Latest Stock Analysis on FDMT</b></p><h2>About 4D Molecular Therapeutics</h2> (Get Free Report)<p>4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.  </p><p>4D's pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.</p><h2>Recommended Stories</h2><ul><li>Five stocks we like better than 4D Molecular Therapeutics</li><li>What is a Stock Market Index and How Do You Use Them?</li><li>Nike Beats on Earnings But Struggles in China and Faces Tariffs</li><li>Why Are These Companies Considered Blue Chips?</li><li>Is the AI Boom a Bubble? These 2 Dividend Stocks Say No</li><li>Trading Stocks: RSI and Why it's Useful</li><li>4 High-Potential ETFs for 2026: Small Caps, Space Stocks, and More</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in 4D Molecular Therapeutics Right Now?</h2><p>Before you consider 4D Molecular Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and 4D Molecular Therapeutics wasn't on the list.</p><p>While 4D Molecular Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

FDMT

<p>Scott Bizily, an insider at 4D Molecular Therapeutics, sold 1,635 shares at $10.90 each, totaling $17,821.50. This sale reduced his ownership by 31.27%, leaving him with 3,594 shares. The transaction was disclosed in an SEC filing. Bizily has made several similar transactions recently. The company's stock is currently trading at $8.68, with a market cap of $495.93 million. Analysts have mixed ratings on the stock, with target prices ranging from $26 to $33.</p>

4D Molecular Therapeutics (NASDAQ:FDMT) Insider Scott Bizily Sells 1,635 Shares